| 马旭明,李 晶,李万鹏,王璐珍,刘 怡,安军钰,黄 晏.血清Irisin、TMAO、MIF与慢性心力衰竭合并心房颤动患者预后的关系及其预测价值研究[J].现代生物医学进展英文版,2024,(11):2145-2149. |
| 血清Irisin、TMAO、MIF与慢性心力衰竭合并心房颤动患者预后的关系及其预测价值研究 |
| Study on the Relationship between Serum Irisin, TMAO, MIF and the Prognosis of Patients with Chronic Heart Failure and Atrial Fibrillation and its Predictive Value |
| Received:November 06, 2023 Revised:November 28, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.11.027 |
| 中文关键词: 慢性心力衰竭 心房颤动 鸢尾素 氧化三甲胺 巨噬细胞迁移抑制因子 预测价值 |
| 英文关键词: Chronic heart failure Atrial fibrillation Irisin Trimethylamine oxide Macrophage migration inhibitory factor |
| 基金项目:甘肃省卫生厅科研基金项目（GSWSK2016-02） |
|
| Hits: 234 |
| Download times: 154 |
| 中文摘要: |
| 摘要 目的：探讨血清鸢尾素（Irisin）、氧化三甲胺（TMAO）、巨噬细胞迁移抑制因子（MIF）与慢性心力衰竭（CHF）合并心房颤动（AF）患者预后的关系及其预测价值。方法：选取2020年1月～2023年1月甘肃省人民医院收治的CHF合并AF患者175例纳入合并AF组，根据预后情况分为预后不良组和预后良好组。另选取同期收治未合并AF的CHF患者100例纳入未合并AF组。通过酶联免疫吸附法检测血清Irisin、TMAO、MIF水平。采用多因素Logistic回归分析CHF合并AF患者预后的影响因素，受试者工作特征（ROC）曲线分析血清Irisin、TMAO、MIF对CHF合并AF患者预后不良的预测价值。结果：与未合并AF组比较，合并AF组血清Irisin水平降低，血清TMAO、MIF水平升高（P＜0.05）。与预后良好组比较，预后不良组血清Irisin水平降低，血清TMAO、MIF水平升高（P＜0.05）。随访6个月，175例CHF合并AF患者预后不良发生率为26.29%。多因素Logistic回归分析显示，纽约心脏病协会（NYHA）心功能分级Ⅲ～Ⅳ级和N末端前体B型钠尿肽（NT-proBNP）、TMAO、MIF升高为CHF合并AF患者预后不良的独立危险因素，Irisin升高为独立保护因素（P＜0.05）。ROC曲线分析显示，血清Irisin、TMAO、MIF联合预测CHF合并AF患者预后不良的曲线下面积（AUC）为0.919，大于血清Irisin、TMAO、MIF单独预测的0.787、0.780、0.777。结论：CHF合并AF患者血清Irisin水平降低，TMAO、MIF水平升高，且与预后不良密切相关。血清Irisin、TMAO、MIF水平联合检测对CHF合并AF患者预后不良具有较高的预测价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum irisin (Irisin), trimethylamine oxide (TMAO), macrophage migration inhibitory factor (MIF) and the prognosis of patients with chronic heart failure (CHF) and atrial fibrillation (AF) and its predictive value. Methods: 175 patients with CHF and AF admitted to Gansu Provincial People's Hospital from January 2020 to January 2023 were selected and included in combined AF group, patints were divided into poor prognosis group and good prognosis group according to the prognosis. And 100 CHF patients without AF during the same period were included in non-combined AF group. The levels of serum Irisin, TMAO and MIF were detected by enzyme-linked immunosorbent assay. The prognostic influencing factors of patients with CHF and AF were analyzed by multivariate logistic regression, the predictive value of serum Irisin, TMAO and MIF in the poor prognosis of patients with CHF and AF were analyzed by receiver operating characteristic (ROC) curve. Results: Compared with non-combined AF group, the serum Irisin level in AF group was decreased, and the serum TMAO and MIF levels were increased (P<0.05). Compared with good prognosis group, the serum Irisin level in poor prognosis group was decreased, and the serum TMAO and MIF levels were increased (P<0.05). After 6 months of follow-up, the incidence of poor prognosis in 175 patients with CHF and AF was 26.29%. Multivariate Logistic regression analysis showed that, New York Heart Association (NYHA) classification of cardiac function III～IV level and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), TMAO, and MIF were independent risk factors for poor prognosis in patients with CHF and AF, and elevated Irisin was an independent protective factor (P<0.05). ROC curve analysis showed that, the area under the curve (AUC) of serum Irisin, TMAO and MIF combined prediction for poor prognosis of patients with CHF and AF was 0.919, which was greater than 0.787, 0.780 and 0.777 predicted by serum Irisin, TMAO and MIF alone. Conclusion: The level of serum Irisin in patients with CHF and AF was decreased, and the levels of TMAO and MIF were increased, which were closely relate to the poor prognosis. The combine detection of serum Irisin, TMAO and MIF levels had a high predictive value for the poor prognosis of patients with CHF and AF. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
